Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?

被引:99
|
作者
Mawdsley, S [1 ]
Glynne-Jones, R
Grainger, J
Richman, P
Makris, A
Harrison, M
Ashford, R
Harrison, RA
Osborne, M
Livingstone, JI
Meyrick-Thomas, J
Northover, JMA
Windsor, A
Novell, R
Wallace, M
机构
[1] Mt Vernon Canc Ctr, Northwood HA6 2RN, Middx, England
[2] Barnet Gen Hosp, Barnet, England
[3] Watford Dist Gen Hosp, Watford, England
[4] Northwick Pk Hosp & Clin Res Ctr, Harrow HA1 3UJ, Middx, England
[5] Luton & Dunstable Gen Hosp, Luton, Beds, England
关键词
preoperative chemoradiotherapy; rectal adenocarcinoma; tumor downstaging; circumferential resection margin; prognostic factors;
D O I
10.1016/j.ijrobp.2005.03.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study set out to determine the impact of a positive circumferential resection margin (CRM) (R1-R2) and pathologic downstaging on local recurrence and survival in patients with borderline resectable or unresectable rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy (CRT). Methods and Materials: A total of 150 patients with locally advanced rectal cancer were treated with long-course neoadjuvwnt CRT-using low-dose folinic acid and 5-fluorouracil. CRT was followed 6-12 weeks later by surgical excision. The CRM rate and incidence, site, and pattern of local and systemic recurrences were recorded. The median follow-up was 25 months. Results: The overall median survival was 37 months, with a 5-year overall survival rate of 34%. Of the 150 patients, 122 -underwent curative resection; 12% had a complete pathologic response, and downstaging to pT1-T2 occurred in an additional 16%. A negative CRM (R0) was achieved in 65% overall (98 of 150). Local recurrence occurred in 10% of those with R0 resection and 62% of those with R1-R2 resections. Distant metastases occurred in 29% of those with R0 resections and 75% of those with R1-R2 resections. The 3-year disease-free and 3-year overall survival rate was 9% and 25% and 52% and 64%, respectively, for patients with and without a histologically positive CRM. Conclusion: After 5-fluorouracil- based CRT, a positive CRM predicted for a high risk of subsequent local r-ecurrence and a 3-year disease-free survival rate of only 9%. For this reason, the CRM should be considered a major prognostic factor and should be validated in future trials as an early alternative clinical endpoint. (c) 2005 Elsevier Inc.
引用
收藏
页码:745 / 752
页数:8
相关论文
共 50 条
  • [21] Genetic variations in the PI3K/PTEN/AKT/mTOR pathway predict tumor response and disease-free survival in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy and radical surgery
    Peng, Jianhong
    Ma, Wenjuan
    Zhou, Zhongguo
    Gu, Yangkui
    Lu, Zhenhai
    Zhang, Rongxin
    Pan, Zhizhong
    JOURNAL OF CANCER, 2018, 9 (06): : 1067 - 1077
  • [22] Quality of surgery in T3-4 rectal cancer: Involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC trial 22921
    den Dulk, Marcel
    Collette, Laurence
    van de Velde, Cornelis J. H.
    Marijnen, Corrie A. M.
    Calais, Gilles
    Mineur, Laurent
    Maingon, Phillippe
    Radosevic-Jelic, Ljijana
    Daban, Alain
    Bosset, Jean-Francois
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (12) : 1821 - 1828
  • [23] Impact of Lateral Pelvic Lymph Node Dissection on the Survival of Patients with T3 and T4 Low Rectal Cancer
    Heita Ozawa
    Kenjiro Kotake
    Miki Hosaka
    Akira Hirata
    Kenichi Sugihara
    World Journal of Surgery, 2016, 40 : 1492 - 1499
  • [24] Impact of Lateral Pelvic Lymph Node Dissection on the Survival of Patients with T3 and T4 Low Rectal Cancer
    Ozawa, Heita
    Kotake, Kenjiro
    Hosaka, Miki
    Hirata, Akira
    Sugihara, Kenichi
    WORLD JOURNAL OF SURGERY, 2016, 40 (06) : 1492 - 1499
  • [25] A Preoperative Neutrophil to Lymphocyte Ratio of 3 Predicts Disease-Free Survival After Curative Elective Colorectal Cancer Surgery
    Malietzis, George
    Giacometti, Marco
    Askari, Alan
    Nachiappan, Subramanian
    Kennedy, Robin H.
    Faiz, Omar D.
    Aziz, Omer
    Jenkins, John T.
    ANNALS OF SURGERY, 2014, 260 (02) : 287 - 292
  • [26] Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study
    Taylor, Fiona G. M.
    Quirke, Philip
    Heald, Richard J.
    Moran, Brendan J.
    Blomqvist, Lennart
    Swift, Ian R.
    Sebag-Montefiore, David
    Tekkis, Paris
    Brown, Gina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (01) : 34 - U114
  • [27] Effect of laparoscopy-assisted vs open surgery on 3-year disease-free survival in patients with low rectal cancer: The LASRE randomized clinical trial.
    Chi, Pan
    Su, Xiangqian
    Xu, Jianmin
    Qiu, Huizhong
    Wang, Ziqiang
    Kang, Liang
    Deng, Haijun
    Chen, Weiping
    Zhang, Qingtong
    Du, Xiaohui
    Yang, Chunkang
    Guo, Yincong
    Zhong, Ming
    Ye, Kai
    You, Jun
    Xu, Dongbo
    Li, Xinxiang
    Xiong, Zhiguo
    Tao, Kaixiong
    Ding, Ke-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 8 - 8
  • [28] Serious adverse events in the EORTC randomized phase III trial 22921 comparing preoperative pelvic irradiation to preoperative chemo-irradiation with or without post-operative adjuvant chemotherapy for T3-T4 resectable rectal cancer
    Musat, E.
    Bosset, J.
    Calais, G.
    Mineur, L.
    Maingon, P.
    Radosevic-Jelic, L.
    Daban, A.
    Bardet, E.
    Beny, A.
    Collette, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 171 - 172
  • [29] INTEGRATED PET/MRI IMAGING BIOMARKERS TO PREDICT HISTOLOGICAL TUMOUR REGRESSION AND 3-YEAR DISEASE FREE SURVIVAL (DFS) IN LOCALLY ADVANCED RECTAL CANCER (LARC).
    Jalil, O.
    Arulampalam, T.
    Motson, R.
    Groves, A.
    Won, S.
    DISEASES OF THE COLON & RECTUM, 2017, 60 (06) : E491 - E491
  • [30] Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (The ADORE).
    Hong, Yong Sang
    Nam, Byung-Ho
    Kim, Kyu-Pyo
    Lee, Jae-Lyun
    Park, Joon Oh
    Park, Young Suk
    Kim, Sun Young
    Kim, Tae-You
    Kim, Jee Hyun
    Ahn, Joong Bae
    Jung, Kyung Hae
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)